Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy
- 8 May 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 27 (1), 117-129
- https://doi.org/10.1038/s41418-019-0343-4
Abstract
Pro-survival stress-inducible chaperone HSP110 is the only HSP for which a mutation has been found in a cancer. Multicenter clinical studies demonstrated a direct association between HSP110 inactivating mutation presence and excellent prognosis in colorectal cancer patients. Here, we have combined crystallographic studies on human HSP110 and in silico modeling to identify HSP110 inhibitors that could be used in colorectal cancer therapy. Two molecules (foldamers 33 and 52), binding to the same cleft of HSP110 nucleotide-binding domain, were selected from a chemical library (by co-immunoprecipitation, AlphaScreening, Interference-Biolayer, Duo-link). These molecules block HSP110 chaperone anti-aggregation activity and HSP110 association to its client protein STAT3, thereby inhibiting STAT3 phosphorylation and colorectal cancer cell growth. These effects were strongly decreased in HSP110 knockdown cells. Foldamer’s 33 ability to inhibit tumor growth was confirmed in two colorectal cancer animal models. Although tumor cell death (apoptosis) was noted after treatment of the animals with foldamer 33, no apparent toxicity was observed, notably in epithelial cells from intestinal crypts. Taken together, we identified the first HSP110 inhibitor, a possible drug-candidate for colorectal cancer patients whose unfavorable outcome is associated to HSP110.Keywords
This publication has 48 references indexed in Scilit:
- Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2018
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 2017
- HSP110 promotes colorectal cancer growth through STAT3 activationOncogene, 2016
- Extracellular HSP110 skews macrophage polarization in colorectal cancerOncoImmunology, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Patients With Colorectal Tumors With Microsatellite Instability and Large Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil–Based ChemotherapyGastroenterology, 2014
- The heat shock proteins as targets for radiosensitization and chemosensitization in cancerCancer Biology & Therapy, 2011
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Heat Shock Protein 70 Neutralization Exerts Potent Antitumor Effects in Animal Models of Colon Cancer and MelanomaCancer Research, 2006
- Heat shock proteins in cancer: chaperones of tumorigenesisTrends in Biochemical Sciences, 2006